BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36752816)

  • 21. JAK protein kinase inhibitors.
    Thompson JE
    Drug News Perspect; 2005 Jun; 18(5):305-10. PubMed ID: 16193102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
    Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
    Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
    Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
    Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
    Liu KD; Gaffen SL; Goldsmith MA; Greene WC
    Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
    Kim HO
    Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
    Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
    Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Janus kinases (Jaks).
    Yamaoka K; Saharinen P; Pesu M; Holt VE; Silvennoinen O; O'Shea JJ
    Genome Biol; 2004; 5(12):253. PubMed ID: 15575979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
    Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
    Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
    Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
    PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
    Vainchenker W; Dusa A; Constantinescu SN
    Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
    Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
    Alunno A; Padjen I; Fanouriakis A; Boumpas DT
    Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers.
    Qiu Q; Chi F; Zhou D; Xie Z; Liu Y; Wu H; Yin Z; Shi W; Qian H
    J Med Chem; 2023 Apr; 66(8):5753-5773. PubMed ID: 37057760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress on the Pharmacological Targeting of Janus Pseudokinases.
    Henry SP; Jorgensen WL
    J Med Chem; 2023 Aug; 66(16):10959-10990. PubMed ID: 37578217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner.
    Krishnan K; Pine R; Krolewski JJ
    Eur J Biochem; 1997 Jul; 247(1):298-305. PubMed ID: 9249040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode.
    Zhao L; Liang Q; He Y; Liu M; Tong R; Jiang Z; Wang W; Shi J
    Bioorg Chem; 2022 Dec; 129():106181. PubMed ID: 36302332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor.
    Kato JY; Korenaga S; Iwakura M
    Bioorg Med Chem Lett; 2023 Jan; 79():129083. PubMed ID: 36414177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of the Janus kinase/signal transducer and activator of transcription pathway by osmotic shock.
    Gatsios P; Terstegen L; Schliess F; Häussinger D; Kerr IM; Heinrich PC; Graeve L
    J Biol Chem; 1998 Sep; 273(36):22962-8. PubMed ID: 9722518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
    Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
    Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.